하지불안증후군 치료의 최신지견
Updates on the Treatment of Restless Leg Syndrome
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
하지불안증후군은 다리나 팔을 움직이고 싶은 충동과 사지의 불쾌한 이상감각을 주 증상으로 하는 수면장애이다. 하지불안증후군의 치료는 그 원인과 증상의 심각도, 빈도에따라 다양하게 접근 할 수 있으며 이차성 하지불안증후군의경우에는 원인 파악과 해결이 선행되어야 한다. 이제까지일차성 하지불안증후군의 치료에 도파민효현제가 일차치료제로 사용되어 왔으나, 우수한 효능에도 불구하고 약물의흔한 부작용인 증강현상으로 인해, 최근 치료 방침은 pregabalin과gabapentin등의 항경련제를 우선적으로 처방하는 것으로 변경되었다. 항경련제나 도파민효현제로 적절히치료되지 않는 경우에는 철분제제, 아편양제제, 벤조디아제핀 등이 사용될 수 있다. 하지불안증후군은 만성질환이기때문에 치료효과와 부작용을 고려한 장기적인 치료계획 수립이 중요하다.
Abstract
Restless legs syndrome (RLS) is a sleep disorder characterized by an urge to move the legs or arms and uncomfortable paresthesia in the legs. Treatment of RLS can be various depending on the causes, severity, and frequency of the symptoms. In the case of secondary RLS, it is important to identify and manage the cause of RLS. Dopamine agonists have been used as firstline treatments for primary RLS treatment. However, due to augmentation, which is a common side effect of dopamine agonists, recent treatment guidelines are changing to prefer to anticonvulsants such as pregabalin and gabapentin. Iron, opioid, or benzodiazepine may be used when anticonvulsants or dopamine agonists are not adequately treated. Because RLS is a chronic disease, it is essential to establish a long-term treatment plan considering both efficacy and side effects.
참고문헌 (24)
- Adler CH, "Treatment of restless legs syndrome with gabapentin", Clin Neuropharmacol, 20, pp.148~151 (1997)[DOI]
- Allen RP, "Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial", Sleep Med, 12, pp.906~913 (2011)[DOI]
- Allen RP, "Comparison of pregabalin with pramipexole for restless legs syndrome", N Engl J Med, 370, pp.621~631 (2014)[DOI]
- Allen RP, "Augmentation of the restless legs syndrome with carbidopa", levodopa, 1996, pp.19, 205~213
- Allen RP, "Principles and Practice of Sleep Medicine", pp.923~934 (2017), Elsevier
- Allen RP, "Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample", Sleep Med, 12, pp.431~439 (2011)[DOI]
- Bogan RK, "Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study", Mayo Clin Proc, 85, pp.512~521 (2010)[DOI]
- Garcia-Borreguero D, "Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study", Neurology, 59, pp.1573~1579 (2002)[DOI]
- Garcia-Borreguero D, "Guidelines for the first-line treatment of restless legs syndrome", Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation, 2016, pp.21, 1~11
- Kang SG, "Characteristics and clinical correlates of restless legs syndrome in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1078~1083 (2007)[DOI]
- Koo YS, "Transcranial direct current stimulation on primary sensorimotor area has no effect in patients with drug-naive restless legs syndrome: a proof-of-concept clinical trial", Sleep Med, 16, pp.280~287 (2015)[DOI]
- Kurlan R, "Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy", J Parkinsonism Restless Legs Syndr, 3, pp.49~52 (2013)
- Lettieri CJ, "Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial", Chest, 135, pp.74~80 (2009)[DOI]
- Manconi M, "Dissociation of periodic leg movements from arousals in restless legs syndrome", Ann Neurol, 71, pp.834~844 (2012)[DOI]
- Mellick GA, "Management of restless legs syndrome with gabapentin (Neurontin)", Sleep, 19, pp.224~226 (1996)[DOI]
- Mitchell UH, "Restless legs syndrome and near-infrared light: An alternative treatment option", Physiother Theory Pract, 27, pp.345~351 (2011)[DOI]
- Montplaisir J, "Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial", Mov Disord, 21, pp.1627~1635 (2006)[DOI]
- Montplaisir J, "Restless legs syndrome improved by pramipexole: a double-blind randomized trial", Neurology, 52, pp.938~943 (1999)[DOI]
- Phillips B, "Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll", Chest, 129, pp.76~80 (2006)[DOI]
- Rios Romenets S, "Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease", Parkinsonism Relat Disord, 19, pp.92~94 (2013)[DOI]
- Ulfberg J, "Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms", Mov Disord, 16, pp.1159~1163 (2001)[DOI]
- Winkelman JW, "Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology", Neurology, 87, pp.2585~2593 (2016)[DOI]
- Winkelman JW, "Augmentation and tolerance with longterm pramipexole treatment of restless legs syndrome (RLS)", Sleep Med, 5, pp.9~14 (2004)[DOI]
- Winkelman JW, "Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study", Neurology, 70, pp.35~42 (2008)[DOI]